Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q1 FY27 revenue 433.6cr +35.7% y-y; EBITDA 90.3cr +122.4% y-y; PAT 61cr +151% y-y - FY27 revenue guidance 1550-1650cr; EBITDA guidance 240-250cr excluding 25cr inventory gain - Gross margin Q1 at 37.9%, sustainable normalized gross margin expected at 30-32% - Phase 1 capex of 250-300cr for capacity debottlenecking and expansions; Phase 2 targets new R&D products - Mahad plant utilization improved from 13% in FY24 to 44% in FY26; EBITDA positive and expected to reach 70% utilization by year-end - Focus on specialty chemicals with 40-40-20 revenue mix; R&D pipeline includes 40 products with 15-20% commercial conversion - Working capital cycle around 60-70 days; strong global distribution with stock points in US, Europe, China - Management conservative on FY27 EBITDA guidance due to geopolitical uncertainties; end-year EBITDA margin expected 15-16%